Scholars@Duke
John Howard Sampson

John Howard Sampson

Robert H., MD and Gloria Wilkins Professor Emeritus of Neurosurgery
Neurosurgery
john.sampson@duke.edu
Box 3810 Med Ctr, Durham, NC 27710
1293 Orange Zone, Duke South, 200 Trent Dr, Durham, NC 27710

Scholarly Works - Conferences

Phase 2 study of bizaxofusp, an IL-4R targeted toxin payload, in nonresectable recurrent GBM: Comparison of overall survival with contemporaneous eligibility-matched and propensity score balanced external control arm.

Conference Journal of Clinical Oncology · June 1, 2024 2079Background: Bizaxofusp (MDNA55) is designed to selectively deliver a potent toxin payload to tumor cells by targeting the IL-4 receptor (IL-4R) overexpressed by GBM, but not normal brain. Localized delivery of bizaxofusp minimizes risk of off-target to ... Full text Cite

Outcomes and immune response after peptide vaccination targeting human cytomegalovirus antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma

Conference Journal of Clinical Oncology · January 1, 2024 Background: The human cytomegalovirus (CMV) antigen pp65 is ubiquitously expressed in high-grade glioma (HGG) and medulloblastoma but not in adjacent brain. The primary objective of this first-in-human phase I trial (NCT03299309) was to assess the safety a ... Full text Cite

A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convectionenhanced delivery for adult patients with recurrent malignant glioma (MG).

Conference JOURNAL OF CLINICAL ONCOLOGY · 2022 Background: D2C7 immunotoxin (D2C7-IT) is a dual-specific recombinant immunotoxin comprising an EGFR wild-type and mutant-specific (EGFRvIII) monoclonal antibody (Ab) fragment and a genetically engineered form of the Pseudomonas exotoxin. When injected dir ... Full text Link to item Cite

A phase 0/surgical window-of-opportunity study in progress, evaluating evolocumab in patients with high-grade glioma or glioblastoma

Conference JOURNAL OF CLINICAL ONCOLOGY · 2022 Background: High-grade gliomas (HGGs) are immunologically ‘cold’ tumors. This phenomenon is partly due to reduced expression of major histocompatibility class (MHC) I on the surface of tumor cells, which prevents CD8+ cytotoxic T lymphocyte activity (CTLs) ... Full text Link to item Cite

CTIM-10. REPRODUCIBILITY OF CLINICAL TRIALS USING CMV-TARGETED DENDRITIC CELL VACCINES IN PATIENTS WITH GLIOBLASTOMA

Conference Neuro-Oncology · November 12, 2021 AbstractINTRODUCTIONVaccination with dendritic cells (DCs) fares poorly in primary and recurrent glioblastoma (GBM). Moreover, GBM vac ... Full text Open Access Link to item Cite

CTIM-21. PEPTIDE VACCINE DIRECTED TO CMV pp65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL

Conference Neuro-Oncology · November 9, 2020 AbstractINTRODUCTIONThe cytomegalovirus (CMV) antigen, pp65, is ubiquitously expressed in malignant glioma and medulloblastoma but not ... Full text Open Access Link to item Cite

Abstract A80: The effects of CCL3 on dendritic cell migration and immune cell activation

Conference Cancer Immunology Research · April 1, 2020 AbstractGlioblastoma (GBM) remains uniformly lethal and current therapy is ineffective and incapacitating. Standard therapies are limited by nonspecific toxicity, and the median overall survival for patients ... Full text Cite

Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.

Conference Journal of Clinical Oncology · May 20, 2019 e13526 Background: Recurrence of high-grade glioma (HGG) (WHO grade III-IV) is a nearly universal phenomenon and necessitates the development of new therapeutic modalities. Two possible immunotherapeutic modalities are checkpoint ... Full text Cite

Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.

Conference Journal of Clinical Oncology · May 20, 2019 2060 Background: We completed a study evaluating a single intratumoral delivery of PVSRIPO in recurrent WHO grade IV MG patients (N Engl J Med. 2018 Jul 12;379(2):150-161). Some patients who originally benefitted from the infusion of PVSRIPO demonstrated ... Full text Link to item Cite

MDNA55: A locally administered IL4 guided toxin as a targeted treatment for recurrent glioblastoma.

Conference Journal of Clinical Oncology · May 20, 2019 2039 Background: IL4 receptor (IL4R) is frequently and intensely expressed on a variety of human cancers and is associated with poor survival outcomes. Determining the role of the IL4R biomarker in glioblastoma (GBM) will be impo ... Full text Link to item Cite

The effect of adoptive transfer of ex vivo activated T cells on the efficacy and tumor penetrance of intravenously-administered CD3-engaging bispecific antibody.

Conference Journal of Clinical Oncology · March 10, 2019 30 Background: Activated T cells are known to traffic throughout the body including past the blood-brain barrier where they perform routine immune surveillance. Whether activated T cells can be used to enhance the efficacy and de ... Full text Cite

Understanding biological activity, tumor response and pseudoprogression in a phase-IIb study of MDNA55 in adults with recurrent or progressive glioblastoma (GB)

Conference Annals of Oncology · October 1, 2018 5581 Background MDNA55, a novel Interleukin-4 empowered cytokine fused to Pseudomonas exotoxin, binds to IL-4 receptor (IL-4R) overexpressed by GB and immunosuppressive cells of the tumor microenvironment. Understanding biological effects of MDNA55 and def ... Full text Link to item Cite

Abstract CN02-02: Immunotherapy for central nervous system cancers

Conference Molecular Cancer Therapeutics · January 1, 2018 AbstractMalignant primary brain tumors are the most frequent cause of cancer death in children and young adults and account for more deaths than cancer of the kidney or melanoma. Despite hundreds of clinical ... Full text Cite

Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).

Conference Journal of Clinical Oncology · May 20, 2017 e13533 Background: The live attenuated oral poliovirus vaccine was modified to contain a heterologous internal ribosomal entry site stemming from human rhinovirus type 2, creating PVSRIPO. PVSRIPO recognizes CD155, an oncofetal c ... Full text Link to item Cite

Phase 1 single-center, dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma.

Conference Journal of Clinical Oncology · May 20, 2017 e13532 Background: D2C7 immunotoxin (D2C7-IT) is a dual-specific recombinant immunotoxin consisting of EGFR-wt and EGFRvIII monoclonal antibodies with a genetically engineered Pseudomonas exotoxin, PE-38KDEL. The primary objectiv ... Full text Link to item Cite

Tumor stem cell RNA-leaded dedritic cell vaccine for recurrent glioblastoma: a phase 1 trail.

Conference Neurology · April 27, 2017 Objective: To evaluate the feasibility and safety of administering brain tumor stem cell (BTSC) mRNA-loaded dendritic cells (DC) to patients with recurrent GBM. Background: BTSC CD133+ contribute to GBM propagation and are associated with chemo-radiation ... Link to item Cite

Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.

Conference Journal of Clinical Oncology · May 20, 2016 Background: The live attenuated oral (SABIN) serotype 1 poliovirus vaccine was modified to contain a heterologous internal ribosomal entry site stemming from human rhinovirus type 2, creating PVSRIPO. PVSRIPO recognizes CD155, an oncofetal cell adhesion mo ... Full text Link to item Cite

Phase I trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM).

Conference Journal of Clinical Oncology · May 20, 2016 ackground: The inherent biologic specificity of immunotherapy offers the prospect of targeting neoplastic cells more precisely. Dendritic cells (DCs) are endowed with an extraordinary ability to activate CD4+ and CD8+ T-cells, and DCs loaded with antigens ... Full text Link to item Cite